Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
-
Published:2021-11-30
Issue:
Volume:
Page:
-
ISSN:1342-1751
-
Container-title:Clinical and Experimental Nephrology
-
language:en
-
Short-container-title:Clin Exp Nephrol
Author:
Sawamura MasatoORCID, Sawa Naoki, Yamanouchi Masayuki, Ikuma Daisuke, Sekine Akinari, Mizuno Hiroki, Kawada Masahiro, Hiramatsu Rikako, Hayami Noriko, Hasegawa Eiko, Suwabe Tatsuya, Hoshino Junichi, Kono Kei, Kinowaki Keiichi, Ohashi Kenichi, Yamaguchi Yutaka, Ubara Yoshifumi
Abstract
Abstract
Background and purpose
We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved renal complications and outcome in patients with rheumatoid arthritis (RA).
Methods
We reviewed records of 156 patients with RA who underwent kidney biopsy at our institute between January 1990 and December 2019. All patients were assigned to one of three periods: period 1, 1990–1999 (n = 48); period 2, 2000–2009(n = 57); period 3, 2010–2019 (n = 51).
Results
Membranous nephropathy, nephrosclerosis, AA-amyloidosis, and IgA nephropathy were the four major renal manifestations of RA. AA-amyloidosis was diagnosed by kidney biopsy in 21 patients: period 1, 7 patients (15%); period 2, 10 patients (18%); and period 3, 4 patients (8%). The 4 patients in period 3 were in the years 2010–2014, and no new case of AA-amyloidosis was recorded from 2015 to 2019. In all 21 of the patients with AA-amyloidosis, neither a biologic agent nor methotrexate was administered. Fifteen of the 21 patients required dialysis, and 13 died in periods 1–3 because of amyloid-related cardiac dysfunction less than 2 years after the initiation of dialysis. Two of them are doing well using biologic agent despite dialysis. The remaining three patients who received a biologic agent or methotrexate does not progress to end-stage renal failure. In addition, the other renal complications showing progression to dialysis also decreased over time.
Conclusion
Advances in treatment strategies have improved renal outcome and reduced mortality in patients with RA.
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Reference14 articles.
1. Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995;38(2):242–7. 2. Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, Kuroda T, Sato T, Maruyama Y, Arakawa M. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50(3):154–60. 3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. 4. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, on behalf of the collaborators developing the Japanese equation for estimating GFR, et al. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92. 5. Hiramatsu R, Hoshino J, Suwabe T, Sumida K, Hasegawa E, Yamanouchi M, Hayami N, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol. 2014;18(1):88–94.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|